Podsumowanie

Dowody epidemiologiczne sugerują, że istnieje zależność odwrotnie proporcjonalna pomiędzy umiarkowanym spożyciem kawy i ryzykiem zachorowania na różnego rodzaju choroby wątroby – nowotwór, zwłóknienie czy marskość wątroby. Dane wskazujące na zależność odwrotnie proporcjonalną pomiędzy spożywaniem kawy i nowotworem wątroby zostały zatwierdzone przez Międzynarodową Agencję do Badań nad Rakiem. Nie wiadomo jednak, czy i do jakiego stopnia kofeina uczestniczy w zmniejszeniu ryzyka wystąpienia wyżej wymienionych chorób wątroby.

Bibliografia

1. European Association for the Study of the Liver (2013) ‘The burden of Liver Disease in Europe: A Review of Available Epidemiological Data’ Available at: http://www.easl.eu/medias/EASLimg/Discover/EU/54ae845caec619f_file.pdf 
2. Eurostat (2007) ‘Europe in Figures: Eurostat yearbook 2006-07’ Available at: http://www.nefmi.gov.hu/letolt/eu/ks_cd_06_001_en.pdf 
3. Ferlay J. et al. (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46(4):765–81.
4. World Health Organisation (2015) ‘Cancer Fact Sheet no.297’. Available at: http://www.who.int/mediacentre/factsheets/fs297/en/
5. Sangiovanni A. et al. (2004) Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterol, 126(4):1005-14.
6. Burroughs A. and McNamara D. (2003) Liver disease in Europe. Alimentary Pharmacol & Therapeutics, 18:54–59.
7. Smart R.G. and Mann R.E. (1992) Alcohol and the epidemiology of liver cirrhosis. Alcohol Health Res World, 16:217-222.
8. Klatsky A.L. et al (1993) Coffee, tea, and mortality. Ann Epidemiol. Jul;3(4):375-81.|
9. Loomis D. et al. (2016) Carcinogenicity of drinking coffee, mate, and very hot beverages. The Lancet Oncology, 17(7):877-878.
10. Bravi F. et al. (2007) Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatol, 46:430-435.
11. Larsson S.C. et al. (2007) Coffee consumption and liver cancer: a meta-analysis. Gastroenterology, 132:1740-1745.
12. Bravi F. et al. (2013) Coffee reduces risk for hepatocellular carcinoma: An updated meta-analysis. Clin Gastro and Hepatol, 11:1413-1421.
13. Leung W.W. et al. (2011) Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case-control study. J Epidemiol & Comm Health, 65:556-558.
14. Jang E.S. et al. (2013) The effect of coffee consumption on the development of hepatocellular carcinoma in hepatitis B virus endemic area. Liver Int, 33(7):1092-1099.
15. Lai G.Y. (2013) The association of coffee intake with liver cancer incidence and chronic liver disease mortality in male smokers. Br J Canc 109:1344–1351.
16. Setiawan V.W. et al. (2015) Association of Coffee Intake with Reduced Incidence of Liver Cancer and Death from Chronic Liver Disease in the US Multiethnic Cohort. Gastroenterol, 148(1):118-125.
17. Saab S. et al. (2014) Impact of coffee on liver disease a systematic review. Liver Int 34(4):495-504.
18. Gressner O.A. (2009) About coffee, cappuccino and connective tissue growth factor – or how to protect your liver!? Enviro Toxicol & Pharmacol, 28(1):1-10.
19. Modi A.A. et al. (2010) Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatol, 51:201-209.
20. Xiao Q. et al. (2014) Inverse association of total and decaffeinated coffee with liver enzymes in NHAMES 1999-2010. Hepatol, published online ahead of print. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25124935
21. Stroffolini T. et al. (2010) Interaction of alcohol intake and cofactors on the risk of cirrhosis. Liver Int, 30(6):867-870.
22. Walton H.B. et al. (2013) An epidemiological study of the association of coffee with chronic liver disease. Scot Med J, 58(4):217-222.
23. Catalano D. et al. (2010) Protective role of coffee on non-alcoholic fatty liver disease (NAFLD). Dig Dis & Sci, 55(11):3200-3206.
24. Birerdinc A. et al. (2012) Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol & Therapeutics, 35(1):76-82.
25. Molloy J.W. et al. (2012) Association of coffee and caffeine consumption with fatty liver disease, non-alcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatol,55(2):429-36.
26. Gutierrez-Grobe Y. et al. (2012) High coffee intake is associated with lower grade non-alcoholic fatty liver disease: the role of peripheral antioxidant activity. Annals Hepatol, 11(3):350-355.
27. Bambha K. et al. (2014) Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver Int. 34(8):1250-8.
28. Freedman N.D. et al. (2009) Coffee intake is associated with lower rates of liver disease progression in chronic Hepatits-C. Hepatol, 50:1360.
29. Costentin C.E. et al. (2011) Association of caffeine intake and histological features of chronic hepatitis C. J Hepatol, Volume 54; 1123-1129.
30. Sasaki Y. et al. (2014) Effect of caffeine containing beverage consumption on serum alanine aminotransferase levels in patients with chronic hepatitis C virus infection: a hospital based cohort study. PLoS One, 8(12):e83382.
31. Goh G.B. et al. (2014) Coffee, alcohol, and other beverages in relation to cirrhosis mortality: the Singapore Chinese Health Study. Hepatol, 60:661-9."
32. Gressner O.A. (2009) Less Smad2 is good for you? A scientific update on coffee’s liver benefits. Hepatol, 50, 970-978.
33. Gressner O.A. et al. (2009) Identification of paraxanthine as the most potent caffeine-derived inhibitor of connective tissue growth factor expression in parenchymal cells. Liver Int, 29(6):886-897.
34. Muriel P. et al. (2010) Coffee and liver disease. Fitoterapia, 81:297-305.
35. Wang G.W. et al. (2009) Anti-hepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid in vivo and in vitro. Antiviral Res, 83(2):186-90.
36. EFSA (2015) Scientific Opinion on the Safety of Caffeine, EFSA Journal, 13(5):4102.
37. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) (2011) Scientific Opinion on the substantiation of health claims related to caffeine and increase in physical performance during short-term high-intensity exercise (ID 737, 1486, 1489), increase in endurance performance (ID 737, 1486), increase in endurance capacity (ID 1488) and reduction in the rated perceived exertion/effort during exercise (ID 1488, 1490) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal; 9(4): 2053 [24 pp.]. doi:10.2903/j.efsa.2011.2053
38. Neuhauser-Berthold M. et al (1997) Coffee consumption and total body water homeostasis as measured by fluid balance and bioelectrical impedance analysis. Ann Nutr Metab, 41(1):29-36.
39. Grandjean A.C. et al (2000) The effect of caffeinated, non caffeinated, caloric and non caloric beverages on hydration. J Am Coll Nutr, 19(5):591-600.
40. Maughan R.J. et al (2003) Caffeine ingestion and fluid balance: a review. J Hum Nutr Diet, 16(6):411-20.
41. Armstrong L.E. et al (2005) Fluid, electrolyte, renal indices of hydration during 11 days of controlled caffeine consumption. Int J Sport Nutr Exerc Metab, 15(3):252-65.
42. Silva A. M. et al (2013) Total body water and its compartments are not affected by ingesting a moderate dose of caffeine in healthy young adult males. Appl Physiol Nutr Metab, 38:626-632.